[
  {
    "ts": null,
    "headline": "Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals",
    "summary": "(Bloomberg) -- President Donald Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on semiconductors could come soon as well, suggesting that those import taxes could hit alongside broad “reciprocal” rates set for implementation on Aug. 1.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearMan",
    "url": "https://finnhub.io/api/news?id=2e64ed0720018a95139fe7b4de57bba326a5f5f91c3662abe605a43aaea27033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752621803,
      "headline": "Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals",
      "id": 135964684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on semiconductors could come soon as well, suggesting that those import taxes could hit alongside broad “reciprocal” rates set for implementation on Aug. 1.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearMan",
      "url": "https://finnhub.io/api/news?id=2e64ed0720018a95139fe7b4de57bba326a5f5f91c3662abe605a43aaea27033"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "summary": "In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=b01b7ff6eb8e6a23f7201524ccf21d6d13a704abb1fcccae06ee4965a8ff0d58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752616205,
      "headline": "Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know",
      "id": 135965225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=b01b7ff6eb8e6a23f7201524ccf21d6d13a704abb1fcccae06ee4965a8ff0d58"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer",
    "summary": "We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the stock market. Its […]",
    "url": "https://finnhub.io/api/news?id=88f4efc059cb880cd4b7ba84c03a9548fa647ec6a1f99bf10f41f83b00f7c19a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752602702,
      "headline": "Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer",
      "id": 135965226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the stock market. Its […]",
      "url": "https://finnhub.io/api/news?id=88f4efc059cb880cd4b7ba84c03a9548fa647ec6a1f99bf10f41f83b00f7c19a"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma plc (VRNA) Is Unlikely To Face Antitrust Action For Merck Deal, Says Jim Cramer",
    "summary": "We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc (NASDAQ:VRNA) is one of the stocks Jim Cramer recently discussed. Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would acquire the firm for a $10 […]",
    "url": "https://finnhub.io/api/news?id=933f67c5dc330aaf89dd435a1e56bde19b602674e0c69b3f88494c8109aba2a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752602683,
      "headline": "Verona Pharma plc (VRNA) Is Unlikely To Face Antitrust Action For Merck Deal, Says Jim Cramer",
      "id": 135957698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc (NASDAQ:VRNA) is one of the stocks Jim Cramer recently discussed. Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would acquire the firm for a $10 […]",
      "url": "https://finnhub.io/api/news?id=933f67c5dc330aaf89dd435a1e56bde19b602674e0c69b3f88494c8109aba2a4"
    }
  },
  {
    "ts": null,
    "headline": "XPH: Healthcare Dashboard For July",
    "summary": "XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade. Click here to find out why XPH stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=f06d8fa42a12451bc189fb589853168778c65a1452470f7473adbf64804e67f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752599588,
      "headline": "XPH: Healthcare Dashboard For July",
      "id": 135956660,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1557045133/image_1557045133.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade. Click here to find out why XPH stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=f06d8fa42a12451bc189fb589853168778c65a1452470f7473adbf64804e67f9"
    }
  },
  {
    "ts": null,
    "headline": "Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention",
    "summary": "MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.",
    "url": "https://finnhub.io/api/news?id=234aa14e8dc531e314ee40bf009e2fc982b9a5437da075a1e80232ad4fd68830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752598440,
      "headline": "Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention",
      "id": 135957302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.",
      "url": "https://finnhub.io/api/news?id=234aa14e8dc531e314ee40bf009e2fc982b9a5437da075a1e80232ad4fd68830"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Mixed as T-Note Yields Rise",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) is unchanged, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU25 ) are up +0.02%, and September E-mini Nasdaq futures (NQU25 )...",
    "url": "https://finnhub.io/api/news?id=c6ce9e29fca5a77a256bd2dce80d18a8325e37ee1884bf4e4c969bbd0009c3ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752595793,
      "headline": "Stocks Mixed as T-Note Yields Rise",
      "id": 135957491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) is unchanged, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU25 ) are up +0.02%, and September E-mini Nasdaq futures (NQU25 )...",
      "url": "https://finnhub.io/api/news?id=c6ce9e29fca5a77a256bd2dce80d18a8325e37ee1884bf4e4c969bbd0009c3ac"
    }
  },
  {
    "ts": null,
    "headline": "American Express, Merck share losses lead Dow's 375-point fall",
    "summary": "American Express, Merck share losses lead Dow's 375-point fall",
    "url": "https://finnhub.io/api/news?id=145b362c2bb7387b4faf720415d1829068ee84a053018c46fd6537a00c3889e6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752584580,
      "headline": "American Express, Merck share losses lead Dow's 375-point fall",
      "id": 135975106,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "American Express, Merck share losses lead Dow's 375-point fall",
      "url": "https://finnhub.io/api/news?id=145b362c2bb7387b4faf720415d1829068ee84a053018c46fd6537a00c3889e6"
    }
  },
  {
    "ts": null,
    "headline": "How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?",
    "summary": "PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.",
    "url": "https://finnhub.io/api/news?id=0314a594a3ab2e3279ed46e07017950680c9defc69730d04f33caa55d120555f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752584040,
      "headline": "How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?",
      "id": 135965230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.",
      "url": "https://finnhub.io/api/news?id=0314a594a3ab2e3279ed46e07017950680c9defc69730d04f33caa55d120555f"
    }
  },
  {
    "ts": null,
    "headline": "Cancer drugmaker LaNova to sell to China’s Sino Biopharm",
    "summary": "Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.",
    "url": "https://finnhub.io/api/news?id=7fdbc6274a20cbe0244e28d10dd6e31b66fe6af682143b518178921ca4ca7db0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752577680,
      "headline": "Cancer drugmaker LaNova to sell to China’s Sino Biopharm",
      "id": 135965231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.",
      "url": "https://finnhub.io/api/news?id=7fdbc6274a20cbe0244e28d10dd6e31b66fe6af682143b518178921ca4ca7db0"
    }
  },
  {
    "ts": null,
    "headline": "Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA",
    "summary": "- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced outcomes from its Type B meeting with the United States F",
    "url": "https://finnhub.io/api/news?id=89ffcca8a3905c83fd65e0d8291d84733b6edcdd2096fb962ef8c432a7274ab4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752577200,
      "headline": "Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA",
      "id": 135965232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced outcomes from its Type B meeting with the United States F",
      "url": "https://finnhub.io/api/news?id=89ffcca8a3905c83fd65e0d8291d84733b6edcdd2096fb962ef8c432a7274ab4"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
    "summary": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
    "url": "https://finnhub.io/api/news?id=46ab8f4b86d2dde50ce7150c01953717a2b163b0c9ffe0eecaf66ec848ffafe1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752575820,
      "headline": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
      "id": 135975426,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
      "url": "https://finnhub.io/api/news?id=46ab8f4b86d2dde50ce7150c01953717a2b163b0c9ffe0eecaf66ec848ffafe1"
    }
  },
  {
    "ts": null,
    "headline": "Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug",
    "summary": "NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.",
    "url": "https://finnhub.io/api/news?id=8809e6d43911ea054913596756bcfd273f9d813e2cf8e07dda612f2c71083d7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752575460,
      "headline": "Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug",
      "id": 135957803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.",
      "url": "https://finnhub.io/api/news?id=8809e6d43911ea054913596756bcfd273f9d813e2cf8e07dda612f2c71083d7e"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
    "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
    "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566400,
      "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
      "id": 135942663,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
      "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5"
    }
  }
]